Symposium 20
Dysfunction of Glutamate, Dopamine, and GABA Neurotransmission in Schizophrenia: Integrative View for Pathophysiologic Analysis and Innovative Treatment

[IS20-3] Neurocognition and NMDAR Co-agonists Pathways in Individuals with Treatment Resistant First-Episode Psychosis

*Kim Q. Do¹, Sara Camporesi^1,2, Lijing Xin³, Philippe Golay², Chin Bin Eap^1,4, Martine Cleusix¹, Michel Cuenod¹, Margot Fournier¹, Kenji Hashimoto⁵, Raoul Jenni¹, Julie Ramain², Romeo Restellini^2,6, Alessandra Solida^2,7, Philippe Conus², Ines Khadimallah¹ (1. Center for Psychiatric Neuroscience, Department of Psychiatry, Lausanne University Hospital, Lausanne, Switzerland, 2. Service of General Psychiatry, Department of Psychiatry, Lausanne University Hospital, Lausanne, Switzerland, 3. Center for Biomedical Imaging, Ecole Polytechnique Fédérale de Lausanne (EPFL), Switzerland, 4. School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, Geneva, Switzerland, 5. Division of Clinical Neuroscience, Chiba University Center for Forensic Mental Health, Chiba, Japan, 6. Emergency Medicine Department, Geneva University Hospital, Geneva, Switzerland , 7. Psychiatry Department for Adults 2, Neuchâtel Centre of Psychiatry, Prefargier, Switzerland)

Keywords:Treatment-resistant schizophrenia, D-serine, Cognition, NMDAR, First-episode psychosis